Web based Drug Database (1.07 Linux)

DICLOFENAC POTASSIUM

Names
Common Name	DICLOFENAC POTASSIUM
Other Name	DICLOFENAC POTASSIUM
Pharmacological Group	NON-STEROIDAL ANTI-INFLAMMATORY DRUGS
Chemical Name	Potassium [o-(2,6-dichloroanilino)phenyl]acetate
Chemical Group

Attributes

Indications	Contraindications	Prescriber Cautions	Patient Cautions
Toxicity	Side Effects	Liver Disease	Renal Failure
Pregnancy	Lactation	Pharmacological Actions	Diagnostic Procedures
Drugs	Interactions

Indications

Low back pain
Gout
Migraine
Crystal arthropathies
Rheumatoid arthritis
Osteoarthritis
Ankylosing spondylitis
Periarthritis
Tendinitis
Synovitis and tenosynovitis
Bursitis
Musculoskeletal pain
Dislocation or subluxation not otherwise specified
Sprains and strains
Postoperative pain

Contraindications

Asthma
Peptic ulcer
Analgesic allergy
Disorders of porphyrin metabolism
Chronic asthmatic bronchitis
Peptic ulcer of oesophagus
Gastric ulcer
Duodenal ulcer
Peptic ulcer - (PU) site unspecified
Gastrojejunal ulcer
Gastritis and duodenitis
Adverse reaction to antirheumatics
Adverse reaction to diclofenac sodium
Airways obstruction reversible
Non-steroidal anti-inflammatory drugs contraindicated

Prescriber Cautions

Consult current official advice regarding DICLOFENAC POTASSIUM
Not recommended for children

Patient Cautions

See information on products containing DICLOFENAC POTASSIUM for specific advice for patients

Toxicity

Epigastric pain
Nausea
Vomiting
Diarrhoea
Headache
Convulsions
Drowsiness
Tinnitus
Coma
Disorientation
Metabolic acidosis
Acute hepatic failure
Acute renal failure
Prothrombin time increased
INR - international normal ratio abnormal

Side Effects

Abdominal cramps - Common
Appetite loss - anorexia - Common
Diarrhoea - Common
Dizziness - Common
Dyspepsia - Common
Epigastric pain - Common
Excessive flatulence - Common
Headache - Common
Liver enzymes abnormal - Common
Nausea - Common
Rash - Common
Vomiting - Common
Acute hepatitis - Rare
Black faeces - Rare
Bronchospasm - Rare
Drowsiness - Rare
Haematemesis - Rare
Jaundice - Rare
Peptic ulcer symptoms - Rare
Tired all the time - Rare
Acute myocardial infarction - Very Rare
Acute pancreatitis - Very Rare
Agranulocytosis - Very Rare
Allergic purpura - Very Rare
Anxiousness - Very Rare
Aplastic anaemia - Very Rare
Blood in urine - haematuria - Very Rare
Blurred Vision - Very Rare
Chest pain - Very Rare
Congestive heart failure - Very Rare
Constipation - Very Rare
Convulsions - Very Rare
Depression - Very Rare
Disorientation - Very Rare
Drug psychoses - Very Rare
Erythema multiforme - Very Rare
Exfoliative dermatitis - Very Rare
Glossitis - Very Rare
Haemolytic anaemia - Very Rare
Hearing difficulty - Very Rare
Hypertension - Very Rare
Impotence - Very Rare
Insomnia - Very Rare
Interstitial nephritis - Very Rare
Intracerebral haemorrhage - Very Rare
Irritability - Very Rare
Leucopenia - Very Rare
Memory loss - amnesia - Very Rare
Meningitis - aseptic - Very Rare
Nephrotic syndrome - Very Rare
Nightmares - Very Rare
Oral aphthae - Very Rare
Palpitations - Very Rare
Paraesthesia - Very Rare
Patches of alopecia - Very Rare
Photosensitiveness - Very Rare
Pneumonitis - Very Rare
Proteinuria - Very Rare
Renal function tests abnormal - Very Rare
Stevens-Johnson syndrome - Very Rare
Taste disturbance - Very Rare
Thrombocytopenia - Very Rare
Tinnitus - Very Rare
Toxic epidermal necrolysis - Very Rare
Tremor - Very Rare
Ulcerative oesophagitis - Very Rare
Vasculitis - Very Rare
Oedema

Liver Disease

Avoid DICLOFENAC POTASSIUM in severe liver disease
DICLOFENAC POTASSIUM causes sodium and water retention in liver disease
DICLOFENAC POTASSIUM - increased risk of gastrointestinal bleeding in liver disease

Renal Failure

Avoid DICLOFENAC POTASSIUM in moderate to severe renal failure
Manufacturer advises reduce dose of DICLOFENAC POTASSIUM in renal failure
DICLOFENAC POTASSIUM - reduces renal function in renal failure
DICLOFENAC POTASSIUM - sodium and water retention in renal failure

Pregnancy

With regular doses of DICLOFENAC POTASSIUM - increased risk of closure of fetal ductus arteriosus in utero & possible persistent pulmonary hypertension of the newborn
Delayed onset & increased duration of labour with increased blood loss
Avoid DICLOFENAC POTASSIUM in the 1st TRIMESTER of pregnancy
Avoid DICLOFENAC POTASSIUM in the 3rd TRIMESTER of pregnancy
Manufacturer advises toxicity of DICLOFENAC POTASSIUM in pregnancy in animal studies

Lactation

Amount of DICLOFENAC POTASSIUM in breast milk too small to be harmful

Pharmacological Actions

ANALGESIC effect
ANTIINFLAMMATORY effect
ANTIPYRETIC effect
CYCLOOXYGENASE INHIBITOR effect

Diagnostic Procedures

- None Listed -

Drugs containing DICLOFENAC POTASSIUM

VOLTAROL RAPID 25mg tablets
VOLTAROL RAPID 50mg tablets
VOLTAROL PAIN-EZE 12.5mg tabs
DICLOFENC POTSSIUM 12.5mg tabs
DICLOFENAC POTASSIUM 25mg tabs
DICLOFENAC POTASSIUM 50mg tabs

Interacting Ingredients

ACECLOFENAC
Likely interaction of DICLOFENAC POTASSIUM increasing the GASTRIC IRRITANT effect of ACECLOFENAC. Moderate risk. May need to avoid combination
ACEMETACIN
Likely interaction of ACEMETACIN increasing the GASTRIC IRRITANT effect of DICLOFENAC POTASSIUM. Moderate risk. May need to avoid combination
ACENOCOUMAROL
Infrequent reports of DICLOFENAC POTASSIUM increasing the ANTICOAGULANT effect of ACENOCOUMAROL. Moderate risk. Monitor
ALOXIPRIN
Likely interaction of ALOXIPRIN increasing the GASTRIC IRRITANT effect of DICLOFENAC POTASSIUM. Moderate risk. May need to avoid combination
AMINOPHYLLINE
Infrequent reports of DICLOFENAC POTASSIUM reducing the BRONCHODILATOR effect of AMINOPHYLLINE. Moderate risk. Avoid
ASPIRIN
Likely interaction of DICLOFENAC POTASSIUM increasing the GASTRIC IRRITANT effect of ASPIRIN. Moderate risk. May need to avoid combination
ASPIRIN [RECTUM]
Likely interaction of DICLOFENAC POTASSIUM increasing the GASTRIC IRRITANT effect of ASPIRIN [RECTUM]. Moderate risk. May need to avoid combination
AZAPROPAZONE
Likely interaction of AZAPROPAZONE increasing the GASTRIC IRRITANT effect of DICLOFENAC POTASSIUM. Moderate risk. May need to avoid combination
BAMBUTEROL HYDROCHLORIDE
Infrequent reports of DICLOFENAC POTASSIUM reducing the BRONCHODILATOR effect of BAMBUTEROL HYDROCHLORIDE. Moderate risk. Avoid
BECLOMETASONE [INHALED]
Infrequent reports of DICLOFENAC POTASSIUM reducing the BRONCHODILATOR effect of BECLOMETASONE [INHALED]. Moderate risk. Avoid
BENORILATE
Likely interaction of BENORILATE increasing the GASTRIC IRRITANT effect of DICLOFENAC POTASSIUM. Moderate risk. May need to avoid combination
BETAMETHASONE
Likely interaction of BETAMETHASONE increasing the GASTRIC IRRITANT effect of DICLOFENAC POTASSIUM. Moderate risk. Monitor
BETAMETHASONE [INHALED]
Infrequent reports of DICLOFENAC POTASSIUM reducing the BRONCHODILATOR effect of BETAMETHASONE [INHALED]. Moderate risk. Avoid
BISMUTH CHELATE
Likely interaction of DICLOFENAC POTASSIUM reducing the ULCER HEALING effect of BISMUTH CHELATE. Moderate risk. Avoid
BUDESONIDE [GASTROINTESTINAL]
Likely interaction of BUDESONIDE [GASTROINTESTINAL] increasing the GASTRIC IRRITANT effect of DICLOFENAC POTASSIUM. Moderate risk. Monitor
BUDESONIDE [INHALED]
Infrequent reports of DICLOFENAC POTASSIUM reducing the BRONCHODILATOR effect of BUDESONIDE [INHALED]. Moderate risk. Avoid
BUFYLLINE
Infrequent reports of DICLOFENAC POTASSIUM reducing the BRONCHODILATOR effect of BUFYLLINE. Moderate risk. Avoid
BUMETANIDE
Theoretical potential for DICLOFENAC POTASSIUM reducing the DIURETIC effect of BUMETANIDE. Moderate risk. Monitor
CANDESARTAN CILEXETIL
Likely interaction of DICLOFENAC POTASSIUM increasing the NEPHROTOXICITY of CANDESARTAN CILEXETIL. Potential risk. Monitor
CARBENOXOLONE
Likely interaction of DICLOFENAC POTASSIUM reducing the ULCER HEALING effect of CARBENOXOLONE. Moderate risk. Avoid
CHOLINE MAGNESIUM TRISALICYLATE
Likely interaction of CHOLINE MAGNESIUM TRISALICYLATE increasing the GASTRIC IRRITANT effect of DICLOFENAC POTASSIUM. Moderate risk. May need to avoid combination
CHOLINE THEOPHYLLINATE
Infrequent reports of DICLOFENAC POTASSIUM reducing the BRONCHODILATOR effect of CHOLINE THEOPHYLLINATE. Moderate risk. Avoid
CICLOSPORIN
Likely interaction of DICLOFENAC POTASSIUM increasing the NEPHROTOXICITY of CICLOSPORIN. Potential risk. Monitor
CIMETIDINE
Likely interaction of DICLOFENAC POTASSIUM reducing the ULCER HEALING effect of CIMETIDINE. Moderate risk. Avoid
CLOPIDOGREL
Theoretical potential for DICLOFENAC POTASSIUM increasing the PLATELET ANTAGONIST effect of CLOPIDOGREL. Moderate risk. May need to avoid combination
COLESTIPOL HYDROCHLORIDE
Likely interaction of COLESTIPOL HYDROCHLORIDE reducing the SERUM LEVEL of DICLOFENAC POTASSIUM. Moderate risk. Monitor
COLESTYRAMINE
Likely interaction of COLESTYRAMINE reducing the SERUM LEVEL of DICLOFENAC POTASSIUM. Moderate risk. Monitor
CORTISONE ACETATE
Likely interaction of CORTISONE ACETATE increasing the GASTRIC IRRITANT effect of DICLOFENAC POTASSIUM. Moderate risk. Monitor
CROMOGLICATE [INHALED]
Infrequent reports of DICLOFENAC POTASSIUM reducing the BRONCHODILATOR effect of CROMOGLICATE [INHALED]. Moderate risk. Avoid
DANAPAROID SODIUM
Theoretical potential for DICLOFENAC POTASSIUM increasing the ANTICOAGULANT effect of DANAPAROID SODIUM. Moderate risk. May need to avoid combination
DEGLYCYRRHIZINISED LIQUORICE
Likely interaction of DICLOFENAC POTASSIUM reducing the ULCER HEALING effect of DEGLYCYRRHIZINISED LIQUORICE. Moderate risk. Avoid
DEXAMETHASONE [ORAL]
Likely interaction of DEXAMETHASONE [ORAL] increasing the GASTRIC IRRITANT effect of DICLOFENAC POTASSIUM. Moderate risk. Monitor
DEXAMETHASONE [PARENTERAL]
Likely interaction of DEXAMETHASONE [PARENTERAL] increasing the GASTRIC IRRITANT effect of DICLOFENAC POTASSIUM. Moderate risk. Monitor
DEXIBUPROFEN
Likely interaction of DICLOFENAC POTASSIUM increasing the GASTRIC IRRITANT effect of DEXIBUPROFEN. Moderate risk. May need to avoid combination
DEXKETOPROFEN
Likely interaction of DEXKETOPROFEN increasing the GASTRIC IRRITANT effect of DICLOFENAC POTASSIUM. Moderate risk. May need to avoid combination
DICLOFENAC SODIUM [ORAL]
Likely interaction of DICLOFENAC POTASSIUM increasing the GASTRIC IRRITANT effect of DICLOFENAC SODIUM [ORAL]. Moderate risk. May need to avoid combination
DICLOFENAC SODIUM [PARENTERAL]
Likely interaction of DICLOFENAC POTASSIUM increasing the GASTRIC IRRITANT effect of DICLOFENAC SODIUM [PARENTERAL]. Moderate risk. May need to avoid combination
DICLOFENAC SODIUM [RECTUM]
Likely interaction of DICLOFENAC POTASSIUM increasing the GASTRIC IRRITANT effect of DICLOFENAC SODIUM [RECTUM]. Moderate risk. May need to avoid combination
DIFLUNISAL
Likely interaction of DIFLUNISAL increasing the GASTRIC IRRITANT effect of DICLOFENAC POTASSIUM. Moderate risk. May need to avoid combination
DIGOXIN
Likely interaction of DICLOFENAC POTASSIUM increasing the SERUM LEVEL of DIGOXIN. Moderate risk. Monitor
DIPROPHYLLINE
Infrequent reports of DICLOFENAC POTASSIUM reducing the BRONCHODILATOR effect of DIPROPHYLLINE. Moderate risk. Avoid
ENOXAPARIN
Likely interaction of DICLOFENAC POTASSIUM increasing the ANTICOAGULANT effect of ENOXAPARIN. Moderate risk. May need to avoid combination
EPHEDRINE HYDROCHLORIDE
Infrequent reports of DICLOFENAC POTASSIUM reducing the BRONCHODILATOR effect of EPHEDRINE HYDROCHLORIDE. Moderate risk. Avoid
EPROSARTAN
Likely interaction of DICLOFENAC POTASSIUM increasing the NEPHROTOXICITY of EPROSARTAN. Potential risk. Monitor
ESOMEPRAZOLE
Likely interaction of DICLOFENAC POTASSIUM reducing the ULCER HEALING effect of ESOMEPRAZOLE. Moderate risk. Avoid
ETODOLAC
Likely interaction of ETODOLAC increasing the GASTRIC IRRITANT effect of DICLOFENAC POTASSIUM. Moderate risk. May need to avoid combination
FAMOTIDINE
Likely interaction of DICLOFENAC POTASSIUM reducing the ULCER HEALING effect of FAMOTIDINE. Moderate risk. Avoid
FENBUFEN
Likely interaction of FENBUFEN increasing the GASTRIC IRRITANT effect of DICLOFENAC POTASSIUM. Moderate risk. May need to avoid combination
FENOPROFEN
Likely interaction of DICLOFENAC POTASSIUM increasing the GASTRIC IRRITANT effect of FENOPROFEN. Moderate risk. May need to avoid combination
FENOTEROL HYDROBROMIDE
Infrequent reports of DICLOFENAC POTASSIUM reducing the BRONCHODILATOR effect of FENOTEROL HYDROBROMIDE. Moderate risk. Avoid
FLUDROCORTISONE ACETATE
Likely interaction of FLUDROCORTISONE ACETATE increasing the GASTRIC IRRITANT effect of DICLOFENAC POTASSIUM. Moderate risk. Monitor
FLURBIPROFEN
Likely interaction of DICLOFENAC POTASSIUM increasing the GASTRIC IRRITANT effect of FLURBIPROFEN. Moderate risk. May need to avoid combination
FLURBIPROFEN [RECTUM]
Likely interaction of DICLOFENAC POTASSIUM increasing the GASTRIC IRRITANT effect of FLURBIPROFEN [RECTUM]. Moderate risk. May need to avoid combination
FLUTICASONE [INHALED]
Infrequent reports of DICLOFENAC POTASSIUM reducing the BRONCHODILATOR effect of FLUTICASONE [INHALED]. Moderate risk. Avoid
FONDAPARINUX SODIUM
Likely interaction of DICLOFENAC POTASSIUM increasing the ANTICOAGULANT effect of FONDAPARINUX SODIUM. Moderate risk. May need to avoid combination
FORMOTEROL
Infrequent reports of DICLOFENAC POTASSIUM reducing the BRONCHODILATOR effect of FORMOTEROL. Moderate risk. Avoid
FUROSEMIDE
Likely interaction of DICLOFENAC POTASSIUM reducing the HYPOTENSIVE effect of FUROSEMIDE. Moderate risk. Monitor
HYDROCORTISONE
Likely interaction of HYDROCORTISONE increasing the GASTRIC IRRITANT effect of DICLOFENAC POTASSIUM. Moderate risk. Monitor
HYDROCORTISONE SODIUM PHOSPHATE
Likely interaction of HYDROCORTISONE SODIUM PHOSPHATE increasing the GASTRIC IRRITANT effect of DICLOFENAC POTASSIUM. Moderate risk. Monitor
HYDROCORTISONE SODIUM SUCCINATE
Likely interaction of HYDROCORTISONE SODIUM SUCCINATE increasing the GASTRIC IRRITANT effect of DICLOFENAC POTASSIUM. Moderate risk. Monitor
IBUPROFEN
Likely interaction of DICLOFENAC POTASSIUM increasing the GASTRIC IRRITANT effect of IBUPROFEN. Moderate risk. May need to avoid combination
IBUPROFEN LYSINE
Likely interaction of DICLOFENAC POTASSIUM increasing the GASTRIC IRRITANT effect of IBUPROFEN LYSINE. Moderate risk. May need to avoid combination
INDACATEROL
Infrequent reports of DICLOFENAC POTASSIUM reducing the BRONCHODILATOR effect of INDACATEROL. Moderate risk. Avoid
INDOMETACIN
Likely interaction of DICLOFENAC POTASSIUM increasing the GASTRIC IRRITANT effect of INDOMETACIN. Moderate risk. May need to avoid combination
INDOMETACIN [RECTUM]
Likely interaction of DICLOFENAC POTASSIUM increasing the GASTRIC IRRITANT effect of INDOMETACIN [RECTUM]. Moderate risk. May need to avoid combination
IRBESARTAN
Likely interaction of DICLOFENAC POTASSIUM increasing the NEPHROTOXICITY of IRBESARTAN. Potential risk. Monitor
ISOETARINE HYDROCHLORIDE
Infrequent reports of DICLOFENAC POTASSIUM reducing the BRONCHODILATOR effect of ISOETARINE HYDROCHLORIDE. Moderate risk. Avoid
ISOPRENALINE HYDROCHLORIDE
Infrequent reports of DICLOFENAC POTASSIUM reducing the BRONCHODILATOR effect of ISOPRENALINE HYDROCHLORIDE. Moderate risk. Avoid
ISOPRENALINE SULPHATE
Infrequent reports of DICLOFENAC POTASSIUM reducing the BRONCHODILATOR effect of ISOPRENALINE SULPHATE. Moderate risk. Avoid
KETOPROFEN
Likely interaction of KETOPROFEN increasing the GASTRIC IRRITANT effect of DICLOFENAC POTASSIUM. Moderate risk. May need to avoid combination
KETOPROFEN [RECTUM]
Likely interaction of KETOPROFEN [RECTUM] increasing the GASTRIC IRRITANT effect of DICLOFENAC POTASSIUM. Moderate risk. May need to avoid combination
KETOROLAC TROMETAMOL
Likely interaction of DICLOFENAC POTASSIUM increasing the PLATELET ANTAGONIST effect of KETOROLAC TROMETAMOL. High risk. Avoid
KETOTIFEN
Infrequent reports of DICLOFENAC POTASSIUM reducing the BRONCHODILATOR effect of KETOTIFEN. Moderate risk. Avoid
LANSOPRAZOLE
Likely interaction of DICLOFENAC POTASSIUM reducing the ULCER HEALING effect of LANSOPRAZOLE. Moderate risk. Avoid
LITHIUM CARBONATE
Likely interaction of DICLOFENAC POTASSIUM increasing the SERUM LEVEL of LITHIUM CARBONATE. Potential risk. Monitor
LITHIUM CHLORIDE [PARENTERAL]
Likely interaction of DICLOFENAC POTASSIUM increasing the SERUM LEVEL of LITHIUM CHLORIDE [PARENTERAL]. Potential risk. Monitor
LITHIUM CITRATE
Likely interaction of DICLOFENAC POTASSIUM increasing the SERUM LEVEL of LITHIUM CITRATE. Potential risk. Monitor
LOSARTAN POTASSIUM
Likely interaction of DICLOFENAC POTASSIUM increasing the NEPHROTOXICITY of LOSARTAN POTASSIUM. Potential risk. Monitor
LYSINE ASPIRIN
Likely interaction of DICLOFENAC POTASSIUM increasing the GASTRIC IRRITANT effect of LYSINE ASPIRIN. Moderate risk. May need to avoid combination
MEFENAMIC ACID
Likely interaction of MEFENAMIC ACID increasing the GASTRIC IRRITANT effect of DICLOFENAC POTASSIUM. Moderate risk. May need to avoid combination
MELOXICAM
Likely interaction of MELOXICAM increasing the GASTRIC IRRITANT effect of DICLOFENAC POTASSIUM. Moderate risk. May need to avoid combination
MELOXICAM [RECTUM]
Likely interaction of MELOXICAM [RECTUM] increasing the GASTRIC IRRITANT effect of DICLOFENAC POTASSIUM. Moderate risk. May need to avoid combination
MESALAZINE
Theoretical potential for DICLOFENAC POTASSIUM increasing the NEPHROTOXICITY of MESALAZINE. Potential risk. May need to avoid combination
METHYLEPHEDRINE
Infrequent reports of DICLOFENAC POTASSIUM reducing the BRONCHODILATOR effect of METHYLEPHEDRINE. Moderate risk. Avoid
METHYLPREDNISOLONE
Likely interaction of METHYLPREDNISOLONE increasing the GASTRIC IRRITANT effect of DICLOFENAC POTASSIUM. Moderate risk. Monitor
MIFEPRISTONE
Theoretical potential for DICLOFENAC POTASSIUM increasing the PROSTANERGIC effect of MIFEPRISTONE. Potential risk. Avoid
MONTELUKAST
Infrequent reports of DICLOFENAC POTASSIUM reducing the BRONCHODILATOR effect of MONTELUKAST. Moderate risk. Avoid
NABUMETONE
Likely interaction of DICLOFENAC POTASSIUM increasing the GASTRIC IRRITANT effect of NABUMETONE. Moderate risk. May need to avoid combination
NAPROXEN
Likely interaction of DICLOFENAC POTASSIUM increasing the GASTRIC IRRITANT effect of NAPROXEN. Moderate risk. May need to avoid combination
NAPROXEN SODIUM
Likely interaction of DICLOFENAC POTASSIUM increasing the GASTRIC IRRITANT effect of NAPROXEN SODIUM. Moderate risk. May need to avoid combination
NAPROXEN [RECTUM]
Likely interaction of DICLOFENAC POTASSIUM increasing the GASTRIC IRRITANT effect of NAPROXEN [RECTUM]. Moderate risk. May need to avoid combination
NEDOCROMIL SODIUM
Infrequent reports of DICLOFENAC POTASSIUM reducing the BRONCHODILATOR effect of NEDOCROMIL SODIUM. Moderate risk. Avoid
NIZATIDINE
Likely interaction of DICLOFENAC POTASSIUM reducing the ULCER HEALING effect of NIZATIDINE. Moderate risk. Avoid
OLMESARTAN MEDOXOMIL
Likely interaction of DICLOFENAC POTASSIUM increasing the NEPHROTOXICITY of OLMESARTAN MEDOXOMIL. Potential risk. Monitor
OMEPRAZOLE [ORAL]
Likely interaction of DICLOFENAC POTASSIUM reducing the ULCER HEALING effect of OMEPRAZOLE [ORAL]. Moderate risk. Avoid
OMEPRAZOLE [PARENTERAL]
Likely interaction of DICLOFENAC POTASSIUM reducing the ULCER HEALING effect of OMEPRAZOLE [PARENTERAL]. Moderate risk. Avoid
ORCIPRENALINE
Infrequent reports of DICLOFENAC POTASSIUM reducing the BRONCHODILATOR effect of ORCIPRENALINE. Moderate risk. Avoid
ORCIPRENALINE [INHALED]
Infrequent reports of DICLOFENAC POTASSIUM reducing the BRONCHODILATOR effect of ORCIPRENALINE [INHALED]. Moderate risk. Avoid
PANTOPRAZOLE
Likely interaction of DICLOFENAC POTASSIUM reducing the ULCER HEALING effect of PANTOPRAZOLE. Moderate risk. Avoid
PENTAZOCINE HYDROCHLORIDE
Infrequent reports of PENTAZOCINE HYDROCHLORIDE increasing the CONVULSANT effect of DICLOFENAC POTASSIUM. Usually no risk. Usually no action necessary
PENTAZOCINE LACTATE
Infrequent reports of PENTAZOCINE LACTATE increasing the CONVULSANT effect of DICLOFENAC POTASSIUM. Usually no risk. Usually no action necessary
PHENINDIONE
Infrequent reports of DICLOFENAC POTASSIUM increasing the ANTICOAGULANT effect of PHENINDIONE. Moderate risk. Monitor
PHENYLBUTAZONE
Likely interaction of PHENYLBUTAZONE increasing the GASTRIC IRRITANT effect of DICLOFENAC POTASSIUM. Moderate risk. May need to avoid combination
PIRBUTEROL
Infrequent reports of DICLOFENAC POTASSIUM reducing the BRONCHODILATOR effect of PIRBUTEROL. Moderate risk. Avoid
PIROXICAM
Likely interaction of PIROXICAM increasing the GASTRIC IRRITANT effect of DICLOFENAC POTASSIUM. Moderate risk. May need to avoid combination
PIROXICAM [RECTUM]
Likely interaction of PIROXICAM [RECTUM] increasing the GASTRIC IRRITANT effect of DICLOFENAC POTASSIUM. Moderate risk. May need to avoid combination
PIROXICAM-BETADEX
Likely interaction of PIROXICAM-BETADEX increasing the GASTRIC IRRITANT effect of DICLOFENAC POTASSIUM. Moderate risk. May need to avoid combination
PREDNISOLONE
Likely interaction of PREDNISOLONE increasing the GASTRIC IRRITANT effect of DICLOFENAC POTASSIUM. Moderate risk. Monitor
PREDNISOLONE ACETATE
Likely interaction of PREDNISOLONE ACETATE increasing the GASTRIC IRRITANT effect of DICLOFENAC POTASSIUM. Moderate risk. Monitor
PREDNISOLONE SODIUM PHOSPHATE
Likely interaction of PREDNISOLONE SODIUM PHOSPHATE increasing the GASTRIC IRRITANT effect of DICLOFENAC POTASSIUM. Moderate risk. Monitor
PREDNISONE
Likely interaction of PREDNISONE increasing the GASTRIC IRRITANT effect of DICLOFENAC POTASSIUM. Moderate risk. Monitor
RABEPRAZOLE
Likely interaction of DICLOFENAC POTASSIUM reducing the ULCER HEALING effect of RABEPRAZOLE. Moderate risk. Avoid
RANITIDINE
Likely interaction of DICLOFENAC POTASSIUM reducing the ULCER HEALING effect of RANITIDINE. Moderate risk. Avoid
RANITIDINE BISMUTH CITRATE
Likely interaction of DICLOFENAC POTASSIUM reducing the ULCER HEALING effect of RANITIDINE BISMUTH CITRATE. Moderate risk. Avoid
REPROTEROL HYDROCHLORIDE
Infrequent reports of DICLOFENAC POTASSIUM reducing the BRONCHODILATOR effect of REPROTEROL HYDROCHLORIDE. Moderate risk. Avoid
RIFAMPICIN
Theoretical potential for RIFAMPICIN reducing the SERUM LEVEL of DICLOFENAC POTASSIUM. Moderate risk. Increase DICLOFENAC POTASSIUM dose
RIMITEROL HYDROBROMIDE
Infrequent reports of DICLOFENAC POTASSIUM reducing the BRONCHODILATOR effect of RIMITEROL HYDROBROMIDE. Moderate risk. Avoid
RITODRINE HYDROCHLORIDE
Infrequent reports of DICLOFENAC POTASSIUM reducing the BRONCHODILATOR effect of RITODRINE HYDROCHLORIDE. Moderate risk. Avoid
SALBUTAMOL
Infrequent reports of DICLOFENAC POTASSIUM reducing the BRONCHODILATOR effect of SALBUTAMOL. Moderate risk. Avoid
SALBUTAMOL [INHALED]
Infrequent reports of DICLOFENAC POTASSIUM reducing the BRONCHODILATOR effect of SALBUTAMOL [INHALED]. Moderate risk. Avoid
SALICYLAMIDE
Likely interaction of SALICYLAMIDE increasing the GASTRIC IRRITANT effect of DICLOFENAC POTASSIUM. Moderate risk. May need to avoid combination
SALIX
Likely interaction of SALIX increasing the GASTRIC IRRITANT effect of DICLOFENAC POTASSIUM. Moderate risk. May need to avoid combination
SALMETEROL XINAFOATE
Infrequent reports of DICLOFENAC POTASSIUM reducing the BRONCHODILATOR effect of SALMETEROL XINAFOATE. Moderate risk. Avoid
SALSALATE
Likely interaction of SALSALATE increasing the GASTRIC IRRITANT effect of DICLOFENAC POTASSIUM. Moderate risk. May need to avoid combination
SODIUM SALICYLATE
Likely interaction of DICLOFENAC POTASSIUM increasing the GASTRIC IRRITANT effect of SODIUM SALICYLATE. Moderate risk. May need to avoid combination
SUCRALFATE
Likely interaction of DICLOFENAC POTASSIUM reducing the ULCER HEALING effect of SUCRALFATE. Moderate risk. Avoid
SULINDAC
Likely interaction of DICLOFENAC POTASSIUM increasing the GASTRIC IRRITANT effect of SULINDAC. Moderate risk. May need to avoid combination
TELMISARTAN
Likely interaction of DICLOFENAC POTASSIUM increasing the NEPHROTOXICITY of TELMISARTAN. Potential risk. Monitor
TENOXICAM
Likely interaction of TENOXICAM increasing the GASTRIC IRRITANT effect of DICLOFENAC POTASSIUM. Moderate risk. May need to avoid combination
TERBUTALINE
Infrequent reports of DICLOFENAC POTASSIUM reducing the BRONCHODILATOR effect of TERBUTALINE. Moderate risk. Avoid
TERBUTALINE [INHALED]
Infrequent reports of DICLOFENAC POTASSIUM reducing the BRONCHODILATOR effect of TERBUTALINE [INHALED]. Moderate risk. Avoid
THEOPHYLLINE
Infrequent reports of DICLOFENAC POTASSIUM reducing the BRONCHODILATOR effect of THEOPHYLLINE. Moderate risk. Avoid
TIAPROFENIC ACID
Likely interaction of TIAPROFENIC ACID increasing the GASTRIC IRRITANT effect of DICLOFENAC POTASSIUM. Moderate risk. May need to avoid combination
TINZAPARIN SODIUM
Likely interaction of DICLOFENAC POTASSIUM increasing the ANTICOAGULANT effect of TINZAPARIN SODIUM. Moderate risk. May need to avoid combination
TOLFENAMIC ACID
Likely interaction of DICLOFENAC POTASSIUM increasing the GASTRIC IRRITANT effect of TOLFENAMIC ACID. Moderate risk. May need to avoid combination
TOLMETIN
Likely interaction of TOLMETIN increasing the GASTRIC IRRITANT effect of DICLOFENAC POTASSIUM. Moderate risk. May need to avoid combination
TORASEMIDE
Theoretical potential for DICLOFENAC POTASSIUM reducing the DIURETIC effect of TORASEMIDE. Moderate risk. Monitor
TRIAMCINOLONE ACETONIDE
Likely interaction of TRIAMCINOLONE ACETONIDE increasing the GASTRIC IRRITANT effect of DICLOFENAC POTASSIUM. Moderate risk. Monitor
TULOBUTEROL HYDROCHLORIDE
Infrequent reports of DICLOFENAC POTASSIUM reducing the BRONCHODILATOR effect of TULOBUTEROL HYDROCHLORIDE. Moderate risk. Avoid
VALSARTAN
Likely interaction of DICLOFENAC POTASSIUM increasing the NEPHROTOXICITY of VALSARTAN. Potential risk. Monitor
VERAPAMIL HYDROCHLORIDE
Theoretical potential for DICLOFENAC POTASSIUM reducing the HYPOTENSIVE effect of VERAPAMIL HYDROCHLORIDE. Usually no risk. Usually no action necessary
WARFARIN SODIUM
Infrequent reports of DICLOFENAC POTASSIUM increasing the ANTICOAGULANT effect of WARFARIN SODIUM. Moderate risk. Monitor
ZAFIRLUKAST
Infrequent reports of DICLOFENAC POTASSIUM reducing the BRONCHODILATOR effect of ZAFIRLUKAST. Moderate risk. Avoid